Literature DB >> 27459363

Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis.

Rachael J Rigby1, Jacquelyn Carr2, Kelly Orgel3,4, Stephanie L King5, P Kay Lund4, Christopher M Dekaney2,5.   

Abstract

Doxorubicin (DOXO) induces significant, but transient, increases in apoptosis in the stem cell zone of the jejunum, followed by mucosal damage involving a decrease in crypt proliferation, crypt number, and villus height. The gastrointestinal tract is home to a vast population of commensal bacteria and numerous studies have demonstrated a symbiotic relationship between intestinal bacteria and intestinal epithelial cells (IEC) in maintaining homeostatic functions of the intestine. However, whether enteric bacteria play a role in DOXO-induced damage is not well understood. We hypothesized that enteric bacteria are necessary for induction of apoptosis and damage associated with DOXO treatment. Conventionally raised (CONV) and germ free (GF) mice were given a single injection of DOXO, and intestinal tissue was collected at 6, 72, and 120 h after treatment and from no treatment (0 h) controls. Histology and morphometric analyses quantified apoptosis, mitosis, crypt depth, villus height, and crypt density. Immunostaining for muc2 and lysozyme evaluated Paneth cells, goblet cells or dual stained intermediate cells. DOXO administration induced significant increases in apoptosis in jejunal epithelium regardless of the presence of enteric bacteria; however, the resulting injury, as demonstrated by statistically significant changes in crypt depth, crypt number, and proliferative cell number, was dependent upon the presence of enteric bacteria. Furthermore, we observed expansion of Paneth and goblet cells and presence of intermediate cells only in CONV and not GF mice. These findings provide evidence that manipulation and/or depletion of the enteric microbiota may have clinical significance in limiting chemotherapy-induced mucositis.

Entities:  

Keywords:  apoptosis; bacteria; damage; doxorubicin; germ free; intestine

Mesh:

Substances:

Year:  2016        PMID: 27459363      PMCID: PMC5046166          DOI: 10.1080/19490976.2016.1215806

Source DB:  PubMed          Journal:  Gut Microbes        ISSN: 1949-0976


  34 in total

1.  CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance.

Authors:  Jan Hendrik Niess; Stephan Brand; Xiubin Gu; Limor Landsman; Steffen Jung; Beth A McCormick; Jatin M Vyas; Marianne Boes; Hidde L Ploegh; James G Fox; Dan R Littman; Hans-Christian Reinecker
Journal:  Science       Date:  2005-01-14       Impact factor: 47.728

Review 2.  Metabolic diversity of the intestinal microbiota: implications for health and disease.

Authors:  Michael Blaut; Thomas Clavel
Journal:  J Nutr       Date:  2007-03       Impact factor: 4.798

3.  The influence of apoptosis on intestinal barrier integrity in rats.

Authors:  Z Sun; X Wang; R Wallen; X Deng; X Du; E Hallberg; R Andersson
Journal:  Scand J Gastroenterol       Date:  1998-04       Impact factor: 2.423

Review 4.  Limitations in doxorubicin production from Streptomyces peucetius.

Authors:  Sailesh Malla; Narayan Prasad Niraula; Bijay Singh; Kwangkyoung Liou; Jae Kyung Sohng
Journal:  Microbiol Res       Date:  2010-01-29       Impact factor: 5.415

5.  Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans.

Authors:  D M Keefe; J Brealey; G J Goland; A G Cummins
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

Review 6.  The role of gut microbiota in immune homeostasis and autoimmunity.

Authors:  Hsin-Jung Wu; Eric Wu
Journal:  Gut Microbes       Date:  2012-01-01

7.  Dysbiosis in inflammatory bowel diseases: the oxygen hypothesis.

Authors:  Lionel Rigottier-Gois
Journal:  ISME J       Date:  2013-05-16       Impact factor: 10.302

8.  Regeneration of intestinal stem/progenitor cells following doxorubicin treatment of mice.

Authors:  Christopher M Dekaney; Ajay S Gulati; Aaron P Garrison; Michael A Helmrath; Susan J Henning
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-09       Impact factor: 4.052

9.  Oxidative/Nitrative Stress and Inflammation Drive Progression of Doxorubicin-Induced Renal Fibrosis in Rats as Revealed by Comparing a Normal and a Fibrosis-Resistant Rat Strain.

Authors:  Csaba Imre Szalay; Katalin Erdélyi; Gábor Kökény; Enikő Lajtár; Mária Godó; Csaba Révész; Tamás Kaucsár; Norbert Kiss; Márta Sárközy; Tamás Csont; Tibor Krenács; Gábor Szénási; Pál Pacher; Péter Hamar
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

10.  Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.

Authors:  Bret D Wallace; Adam B Roberts; Rebecca M Pollet; James D Ingle; Kristen A Biernat; Samuel J Pellock; Madhu Kumar Venkatesh; Leah Guthrie; Sara K O'Neal; Sara J Robinson; Makani Dollinger; Esteban Figueroa; Sarah R McShane; Rachel D Cohen; Jian Jin; Stephen V Frye; William C Zamboni; Charles Pepe-Ranney; Sridhar Mani; Libusha Kelly; Matthew R Redinbo
Journal:  Chem Biol       Date:  2015-09-10
View more
  21 in total

Review 1.  Gut microbiota-immune-brain interactions in chemotherapy-associated behavioral comorbidities.

Authors:  Kelley R Jordan; Brett R Loman; Michael T Bailey; Leah M Pyter
Journal:  Cancer       Date:  2018-07-05       Impact factor: 6.860

Review 2.  The role of the microbiome in cancer development and therapy.

Authors:  Aadra P Bhatt; Matthew R Redinbo; Scott J Bultman
Journal:  CA Cancer J Clin       Date:  2017-05-08       Impact factor: 508.702

3.  FIBCD1 ameliorates weight loss in chemotherapy-induced murine mucositis.

Authors:  Maria C E Andersen; Malene W Johansen; Thomas Nissen; Anders B Nexoe; Gunvor I Madsen; Grith L Sorensen; Uffe Holmskov; Anders Schlosser; Jesper B Moeller; Steffen Husby; Mathias Rathe
Journal:  Support Care Cancer       Date:  2020-09-12       Impact factor: 3.603

4.  Microbes exploit death-induced nutrient release by gut epithelial cells.

Authors:  Christopher B Medina; Brady J Barron; Christopher J Anderson; Laura Karvelyte; Tania Løve Aaes; Irina Lambertz; Justin S A Perry; Parul Mehrotra; Amanda Gonçalves; Kelly Lemeire; Gillian Blancke; Vanessa Andries; Farzaneh Ghazavi; Arne Martens; Geert van Loo; Lars Vereecke; Peter Vandenabeele; Kodi S Ravichandran
Journal:  Nature       Date:  2021-08-04       Impact factor: 49.962

5.  Depletion of enteric bacteria diminishes leukocyte infiltration following doxorubicin-induced small intestinal damage in mice.

Authors:  Jacquelyn S Carr; Stephanie King; Christopher M Dekaney
Journal:  PLoS One       Date:  2017-03-03       Impact factor: 3.240

Review 6.  Intestinal Microbiota: A Novel Target to Improve Anti-Tumor Treatment?

Authors:  Romain Villéger; Amélie Lopès; Guillaume Carrier; Julie Veziant; Elisabeth Billard; Nicolas Barnich; Johan Gagnière; Emilie Vazeille; Mathilde Bonnet
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

7.  Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models.

Authors:  Cindy Pensec; Florence Gillaizeau; Dominique Guenot; Anne Bessard; Thomas Carton; Sébastien Leuillet; Mario Campone; Michel Neunlist; Hervé M Blottière; Françoise Le Vacon
Journal:  Sci Rep       Date:  2020-06-04       Impact factor: 4.379

Review 8.  New Frontiers about the Role of Human Microbiota in Immunotherapy: The Immune Checkpoint Inhibitors and CAR T-Cell Therapy Era.

Authors:  Vanessa Innao; Andrea Gaetano Allegra; Caterina Musolino; Alessandro Allegra
Journal:  Int J Mol Sci       Date:  2020-11-24       Impact factor: 5.923

9.  Chemotherapy-induced neuroinflammation is associated with disrupted colonic and bacterial homeostasis in female mice.

Authors:  B R Loman; K R Jordan; B Haynes; M T Bailey; L M Pyter
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

Review 10.  Emerging Insights on the Interaction Between Anticancer and Immunosuppressant Drugs and Intestinal Microbiota in Pediatric Patients.

Authors:  Marianna Lucafò; Martina Franzin; Cristina Lagatolla; Raffaella Franca; Matteo Bramuzzo; Gabriele Stocco; Giuliana Decorti
Journal:  Clin Transl Sci       Date:  2019-12-04       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.